GIMER starts a 30-patient trial in Taiwan
After several rounds of communications with Taiwan FDA, GIMER Medical has
started a 30-patient trial in Taiwan.
The trial is a short-term, multi-site, randomized, sham-controlled, double-blind trial
with one-way crossover.The trial is recruiting in 4 sites in Taiwan and is expected to
finish by June, 2021.
